Not interested in the ongoing angst re shorting...it's a fact of life and it does provide liquidity so I can't understand why there is so much discussion on a facet of the market which is here to stay. Shorting can be as profitable as straight long investing so it's a legitimate tool for professional investors, (who normally protect their positions with option strategies as well,) so not necessarily something a mere retail investor should involve themselves with.
On another tack, I was interested to see J & J pay $US1.75BN for Alios BioPharma, a US based group which has but 1 (YES 1!) Phase 2 trial undergoing at present. Alios target respiratory diseases.
Correct me if I'm wrong but won't MSB have 4 (YES 4!) Phase 3 trials underway by November? Crazy world out there in my view but simply demonstrates how the Australian institutional market operates. Buy when the first dividend is declared?
MSB Price at posting:
$4.28 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)